Preparation and use of allogeneic universal CAR-T cells targeting CLEC12A
By developing anti-CLEC12A nano-antibody and allogeneic universal CAR-T cells targeting CLEC12A, the problems of long preparation cycle, high cost and limited source of CAR-T cell therapy were solved, and efficient treatment of AML was achieved, which significantly Reduced treatment costs and expanded clinical application prospects.
Patent Information
- Application Number
- CN202311612164.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-11-29
AI Technical Summary
The existing CAR-T cell therapy for acute myeloid leukemia has problems such as long preparation cycle, high cost and limited source, which limits its application in AML therapy.
A nanoantibodies against CLEC12A and allogeneic universal CAR-T cells targeting CLEC12A were developed. Through preparation methods and uses, nanoantibodies are used to bind CAR-T cells to achieve targeted treatment of AML cells.
This method significantly reduces the treatment cost, overcomes the limitations of autologous CAR-T cell preparation, improves the efficiency and feasibility of AML treatment, and provides a broad clinical application prospect.
Smart Images

Figure CN117736327B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to an anti-CLEC12A nanobody, a CLEC12A-targeted allogeneic universal CAR-T cell, and a preparation method and use thereof. Background Art
[0002] Acute myeloid leukemia (AML) is a fatal hematologic malignancy caused by abnormal proliferation of primitive and immature myeloid cells in the bone marrow, peripheral blood, or extramedullary tissues, resulting in a large number of immature cells in the circulation and the replacement of normal bone marrow with malignant cells. The general signs and symptoms of early AML may be similar to those of influenza or other common diseases, mainly manifested by fever, bone pain, lethargy, fatigue, shortness of breath, frequent infections, abnormal bleeding, and easy bruising. The incidence of AML increases with age. It is the most common acute leukemia in adults, with a median age of 50 years. AML can also occur as a secondary tumor after chemotherapy or radiotherapy for another tumor. Most AML patients receive treatment including induction chemotherapy to achieve remission and post-remission chemotherapy (including or excluding stem cell transplantation) to avoid relapse. However, as a highly heterogeneous malignant tumor disease, AML is prone to relapse and develop into a refractory disease even after standard therapy. Therefore, new therapeutic drugs need to be continuously developed to meet the needs of different patients.
[0003] C-type lectin domain family 12 member A (CLEC12A), also known as C-type lectin-like molecule 1 (CLL1), CD371, DCAL-2, MICL, etc. Studies by Bakker et al. showed that CLEC12A is overexpressed in 90%-95% of new or relapsed AML cases and is rarely seen in normal tissues. Unlike CD33 and CD123, CLEC12A is highly expressed in leukemia stem cells (LSCs) and AML cells, but not in megakaryocyte progenitor cells and normal hematopoietic stem cells (HSCs). Its special expression pattern makes CLEC12A a potential effective target for the development of adoptive immunotherapy for the treatment of AML.
[0004] Traditional chemoradiotherapy and hematopoietic stem cell transplantation are inefficient in treating AML, while chimeric antigen receptor T-cell immunotherapy has become a possible treatment for curing AML. Currently, all FDA-approved CAR-T cell therapies targeting CD19 and BCMA are autologous CAR-T, which is an individualized treatment. However, autologous CAR-T cell therapy still has many limiting issues, such as long CAR-T cell preparation cycle, high preparation cost, and reduced number of T cells in patients who have undergone multiple lines of treatment or impaired T cell function, resulting in a decline in quality and making it impossible to use for CAR-T cell preparation. CAR-T cells have shown excellent efficacy in the treatment of B-cell malignancies, but there is an essential difference between myeloid antigens and B-cell antigens. The killing of normal myeloid cells by CAR-T cells will lead to bone marrow failure and there is no corresponding alternative therapy, which makes the CAR-T treatment of AML progress slowly. Based on the special expression pattern of CLEC12A, it is possible to develop adoptive cell immunotherapy targeting CELC12A.
[0005] With the rapid development of various gene editing technologies such as CRISPR / Cas9, it is now possible to knock out genes that mediate inter-individual immune responses, such as TCR, B2M, and CD52, from healthy donor-derived T cells, thereby minimizing GvHD and HvGR, and then preparing "off-the-shelf" allogeneic universal CAR-T cells (UCAR-T). UCAR-T cell therapy can overcome many of the shortcomings of autologous CAR-T cells and can be manufactured on a large scale through standardized processes, thereby realizing the mass production and industrialization of CAR-T cell therapy products, while significantly reducing treatment costs and enabling more patients to benefit.
[0006] In view of this, the present invention is proposed. Summary of the invention
[0007] The technical problem to be solved by the present invention is that in the existing CAR-T treatment research for acute myeloid leukemia, autologous CAR-T cell therapy is generally used, which has problems such as long preparation cycle, high cost, and limited source.
[0008] The technical solution of the present invention to solve the above technical problems is: to provide an anti-CLEC12A nanobody, a CLEC12A-targeted allogeneic universal CAR-T cell, and a preparation method and use thereof.
[0009] In a first aspect of the present invention, an anti-CLEC12A nanobody is provided, wherein the heavy chain variable region of the nanobody comprises CDR1, CDR2 and CDR3, and the amino acid sequences of CDR1, CDR2 and CDR3 are any one of SEQ ID No.1-3, SEQ ID No.5-7, SEQ ID No.9-11 or SEQ ID No.13-15, respectively.
[0010] Among them, in the above-mentioned anti-CLEC12A nanobody, the nanobody also includes a framework region, and the structure of its heavy chain variable region is: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0011] Among them, in the above-mentioned anti-CLEC12A nanobody, the nanobody is at least one of a monovalent nanobody, a multivalent nanobody, a multispecific antibody or a fusion nanobody.
[0012] Preferably, in the above-mentioned anti-CLEC12A Nanobody, when the antibody is a monovalent Nanobody, the amino acid sequence of the heavy chain variable region of the Nanobody is as shown in any one of SEQ ID No. 4, 8, 12 or 16.
[0013] In a second aspect, the present invention provides an antibody comprising the above-mentioned anti-CLEC12A Nanobody or any one heavy chain variable region of the above-mentioned anti-CLEC12A Nanobody.
[0014] In a third aspect of the present invention, a nucleic acid encoding the above-mentioned anti-CLEC12A nanobody is provided. Preferably, the nucleotide sequence of the nucleic acid is shown in SEQ ID No. 17-20.
[0015] SEQ ID No.17 Nucleotide encoding the anti-CLEC12A nanobody Nb22
[0016] CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGAC
[0017] TCTCCTGTACAGCCTCTGGATTCAGTTTTGATGATTCTGACATGGGCTGGTACCGCCAG
[0018] GCTCCAGGGAATGAGTGCGAGATGGTCTCAAGTTTCAGTAGTGATGGTAGCACATTCT
[0019] ATGACGACTCTGTGAAGGGCCGATTCACCATCTCCCAAGACAACGCCAAGAACACGGT
[0020] GTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTGTATTACTGTGCGGCA
[0021] GATGATCGTCTACCCCGCGGTGGTAGCTGGTCTGCATGTCCCCCGGGAGTTGACGTTGGTTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA。
[0022] SEQ ID No.18 Coding nucleotide of nanobody Nb26 against CLEC12A CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTACAGTAACGCCTGTATGGGTTGGTGGCGCCAGGCTCCAGGGAAGGAGCGCGAGGGGGTCGCACAAATTAATACTAGTGGTGGTAGAACATACTATGTCGACTCCGTGAAGGGCCGATTCACCATCTCCCAAGACATCGCCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACTGCCATGTACTATTGTGCGGCAGGCCAGGGTGGTGACTGCTACGGCATGCCTATCTACCCAGGTGACTTTAATTACTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA。
[0023] SEQ ID No.19 Anti-CLEC12A Nanobody Nb41 encoding nucleotide CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGTCTCTGGATACACGTATAGTAGCTACTGCATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGGGGGTCGCAGCTATTGAAAGTGATGGTAGCACAAGCTACG CAGACTCCGTGAAGGGCCGATTCACCATCTCCAAAGACAACGCCAAGAACATTGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACGCTGCCACGTACTACTGTGCCTCAGATGTCGTCGATGTAATAAAGAGTGGTGGTTTGTGCTACAGTGGAGAAGACATGGACTACTGGGGCAAAGGAACCCAGGTCACCGTCTCCTCA.
[0024] SEQ ID No.20 Anti-CLEC12A Nanobody Nb43 encoding nucleotide CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTACAGCCTCTGGATTCACTTTGATGATTCGAACATGGGCTGGTACCGCCAGGTCCAGGGAATGAGTGCGAGTTGGTCTCAAGTATTGGTAGTGACGGTAATAGTGATGGTGTC ACATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCCAAGACAACGCCAAGAACGCGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACGGCCGTGTATCACTGTGCGGCAGATTATTTTCTTGGAATGCGTTGTAGTGGTGGTTTTTCCCTCCCCGTTACTGGGGCCAGGGGGACCCAGGTCACCGTCTCCTCA.
[0025] In a fourth aspect, the present invention provides a recombinant vector comprising the above nucleic acid. Preferably, the recombinant vector is a plasmid or a virus; the virus is an adenovirus, an adeno-associated virus, a retrovirus, a lentivirus or an oncolytic virus.
[0026] In a fifth aspect, the present invention provides a host cell comprising the above-mentioned nucleic acid or recombinant vector.
[0027] Preferably, the host cell is selected from at least one of a prokaryotic host cell, a eukaryotic host cell or a bacteriophage; the prokaryotic host cell includes at least one of Escherichia coli, Streptomyces, Bacillus subtilis or Mycobacterium, and the eukaryotic host cell includes at least one of an animal cell, a plant cell or a fungus; the animal cell is selected from mammalian cells, insect cells or Caenorhabditis elegans; the mammalian cell is selected from any one of 293 cells, 293T cells, 293FT cells, CHO cells, COS cells, mouse L cells, LNCaP cells, 633 cells, Vero, BHK cells, CV1 cells, Hela cells, MDCK cells, Hep-2 cells or Per6 cells; the fungus is selected from any one of Saccharomyces cerevisiae, Pichia pastoris, Hansen's yeast, Candida albicans, Kluyveromyces lactis, Aspergillus nidulans, Schizosaccharomyces pombe or Yarrowia lipolytica.
[0028] In a sixth aspect, the present invention provides a method for preparing the above-mentioned anti-CLEC12A nanobody, comprising the following steps:
[0029] The recombinant vector containing the anti-CLEC12A nanobody of the fourth aspect of the present invention is transduced into the host cell of the fifth aspect by transfection or infection, and the culture supernatant or host cells are collected after expansion and further purified to obtain the recombinant nanobody. Specifically, the present invention does not specifically limit the culture conditions of the host cells, and the culture conditions that enable the host cells to express and produce the antibodies can be obtained based on conventional technical knowledge.
[0030] In a seventh aspect, the present invention provides an immunoconjugate or pharmaceutical composition comprising the above-mentioned anti-CLEC12A nanobody or antibody. The immunoconjugate further comprises a therapeutic agent; the therapeutic agent is at least one of an immune checkpoint-related preparation, a toxin, a factor, a chemotherapeutic drug, a radionuclide, a kinase inhibitor or a cytotoxic agent. The pharmaceutical composition comprises at least one of a pharmaceutical excipient, a carrier or a diluent.
[0031] In an eighth aspect, the present invention provides a chimeric antigen receptor, wherein the antigen binding domain of the chimeric antigen receptor comprises the above-mentioned anti-CLEC12A nanobody or the above-mentioned antibody.
[0032] Preferably, the chimeric antigen receptor further comprises a signal peptide, a hinge region, a transmembrane region and a signal transduction domain. Preferably, the signal transduction domain is selected from at least one of CD3ζ, 4-1BB (CD137), CD27, CD30, CD40, CD54, CD83, PD-1, ICOS (CD278), lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, CD270, CD273, CD274, DAP10, CLEC12A3, CD134, CD150 or CD152; The domain includes CD3ζ and 4-1BB intracellular region; the transmembrane region is one or more of CD28 transmembrane domain, CD8 transmembrane region, CD134 transmembrane region, CD137 transmembrane region, ICOS transmembrane region or DAP10 transmembrane region; the hinge region is at least one of IgG1FC-CH2-CH3 hinge region, IgG2FC-CH2-CH3 hinge region, IgG4FC-CH2-CH3 hinge region, CD28 hinge region or CD8α hinge region;
[0033] The signal peptide is one of CD8α signal peptide, IL-2 signal peptide or GM-CSF signal peptide.
[0034] In a ninth aspect, the present invention provides a CAR-T cell targeting CLEC12A comprising the above-mentioned chimeric antigen receptor.
[0035] Preferably, the CAR-T cells are selected from at least one of allogeneic universal CAR-T cells or autologous CAR-T cells.
[0036] Preferably, the allogeneic universal CAR-T cells are CAR-T cells in which the B2M and TRAC genes are knocked out.
[0037] In a tenth aspect, the present invention provides a use of the above-mentioned anti-CLEC12A nanobody, antibody, nucleic acid, recombinant vector, host cell, chimeric antigen receptor or CAR-T cell in any of the following;
[0038] a. Prepare immune cells, reagents, kits, drugs or pharmaceutical compositions for preventing or treating tumors;
[0039] b. preparing reagents, kits or gene chips for detecting CLEC12A;
[0040] c. Prepare pharmaceutical compositions for combined therapy.
[0041] Preferably, the tumor is a primary tumor or a secondary tumor.
[0042] More preferably, the tumor includes at least one of acute myeloid leukemia, chronic myeloid leukemia or myelodysplastic syndrome.
[0043] Compared with the prior art, the present invention has the following beneficial effects:
[0044] The present invention uses human CLEC12A as the target and prepares anti-CLEC12A nanoantibodies through phage display technology, and all of them can specifically bind to CLEC12A antigen with an affinity of 10 -10 M, all of which are high-affinity nanobodies. Afterwards, the present invention prepared UCAR-T cells targeting CLEC12A, and found that they had anti-tumor activity against CLEC12A-positive tumor cells, which can be applied to the immunotherapy of CLEC12A target-related diseases and have broad clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 The figure shows the binding specificity of anti-CLEC12A nanobody to CLEC12A antigen analyzed by indirect ELISA in Example 1 of the present invention;
[0046] Figure 2 Shown is the expression and purity of the Nb-hFc recombinant nanobody detected by SDS-PAGE in Example 2 of the present invention;
[0047] Figure 3 The figure shows the binding ability of anti-CLEC12A nanobody to CLEC12A antigen analyzed by indirect ELISA in Example 3 of the present invention;
[0048] Figure 4 The figure shows the binding of the recombinant nanobody to THP-1 and U937 cells detected by flow cytometry in Example 5 of the present invention;
[0049] Figure 5 Shown is the knockout efficiency detection of B2M and TRAC in Example 6 of the present invention;
[0050] Figure 6 The figure shows a schematic diagram of the CAR structure in Example 6 of the present invention;
[0051] Figure 7 Shown is the expression efficiency of CAR in Example 6 of the present invention;
[0052] Figure 8 Shown is the killing efficiency test of universal CAR-T cells against CLEC12A positive cell lines THP-1 and U937 in Example 7 of the present invention;
[0053] Fig. 9The figure shows the in vivo anti-tumor effect of universal CAR-T cells evaluated using the NCG mouse xenograft model in Example 8 of the present invention. DETAILED DESCRIPTION
[0054] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0055] The present invention provides an anti-CLEC12A nanobody, wherein the heavy chain variable region of the nanobody comprises CDR1, CDR2 and CDR3, and the amino acid sequences of CDR1, CDR2 and CDR3 are any one of SEQ ID No.1-3, SEQ ID No.5-7, SEQ ID No.9-11 or SEQ ID No.13-15, respectively.
[0056] Among them, in the above-mentioned anti-CLEC12A nanobody, the nanobody also includes a framework region, and the structure of its heavy chain variable region is: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0057] In an alternative embodiment, when the Nanobody is a monovalent Nanobody, the amino acid sequence of the heavy chain variable region of the Nanobody is as shown in any one of SEQ ID No. 4, 8, 12 and 16.
[0058] In a second aspect, the present invention further provides an antibody comprising the above-mentioned anti-CLEC12A Nanobody or the heavy chain variable region (VHH) of the anti-CLEC12A Nanobody.
[0059] The antibody can be any one of a full-length antibody, a heavy chain antibody, a chimeric antibody, a multispecific antibody (e.g., a bispecific antibody, a trispecific antibody, a tetraspecific antibody, etc.), a murine antibody, a humanized antibody, or an antigen-binding fragment. The antigen-binding fragment is selected from any one of F(ab')2, Fab', Fab, Fv, and scFv of an antibody, as long as they exhibit the desired antigen-binding activity.
[0060] The "chimeric antibody" described in the present invention is an antibody formed by fusing the variable region of a non-human antibody with the constant region or framework region of a human antibody, which can reduce the immune response induced by the non-human antibody. The above-mentioned antigen-binding fragment, that is, the functional fragment of the antibody, usually has the same binding specificity as the antibody from which it is derived. It is easy for those skilled in the art to understand based on the contents described in the present invention that the functional fragment of the above-mentioned antibody can be obtained by methods such as enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds. Based on the structure of the complete antibody disclosed in the present invention, those skilled in the art can easily obtain the above-mentioned functional fragment.
[0061] In a third aspect, the present invention further provides a nucleic acid molecule or a recombinant vector comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the above-mentioned anti-CLEC12A nanobody; or the nucleic acid molecule encodes the above-mentioned antibody.
[0062] Taking into account the degeneracy of codons, the gene sequence encoding the above-mentioned antibody can be modified in its coding region without changing the amino acid sequence to obtain a gene encoding the same antibody; the gene can also be artificially synthesized and modified according to the codon preference of the host expressing the antibody to improve the expression efficiency of the antibody.
[0063] The recombinant vector is an expression vector or a cloning vector, preferably an expression vector, which can refer to any recombinant polynucleotide construct that can directly or indirectly (such as packaging into a virus) introduce the target DNA fragment into the host cell through transformation, transfection or transduction to express the target gene.
[0064] One type of vector is a plasmid, which is a circular double-stranded DNA molecule that can connect the target DNA fragment to the plasmid ring. Another type of vector is a viral vector, which can connect and package the target DNA fragment into a viral genome (such as adenovirus, adeno-associated virus, retrovirus, lentivirus, oncolytic virus). After these vectors enter the host cell, they can express the target gene.
[0065] In a fourth aspect, the present invention also provides a host cell containing the above-mentioned recombinant vector.
[0066] In an optional embodiment, the host cell is selected from at least one of a prokaryotic host cell, a eukaryotic host cell and a bacteriophage;
[0067] In an alternative embodiment, the prokaryotic host cell is Escherichia coli, Streptomyces, Bacillus subtilis or Mycobacterium;
[0068] In an alternative embodiment, the eukaryotic host cell is an animal cell, a plant cell or a fungus;
[0069] In an alternative embodiment, the animal cell is selected from a mammalian cell, an insect cell or a Caenorhabditis elegans cell;
[0070] The mammalian cell is selected from any one of 293 cells, 293T cells, 293FT cells, CHO cells, COS cells, mouse L cells, LNCaP cells, 633 cells, Vero, BHK cells, CV1 cells, Hela cells, MDCK cells, Hep-2 cells and Per6 cells. Among them, 293 series cells, Per6 cells and CHO cells are commonly used mammalian cells for producing antibodies or recombinant proteins, and are well known to those of ordinary skill in the art.
[0071] In an alternative embodiment, the fungus is selected from any one of Saccharomyces cerevisiae, Pichia pastoris, Hansenula, Candida, Kluyveromyces lactis, Aspergillus nidulans, Schizosaccharomyces pombe and Yarrowia lipolytica. Candida is, for example, selected from Candida albicans or Candida glabrata.
[0072] In a fifth aspect, the present invention also provides a method for preparing an antibody, comprising: culturing the above-mentioned host cell to obtain the antibody. Specifically, the present invention does not specifically limit the culturing conditions of the host cell, and the culturing conditions that enable the host cell to express and produce the antibody can be obtained based on conventional technical knowledge.
[0073] In a sixth aspect, the present invention further provides an immunoconjugate or a pharmaceutical composition, comprising the above-mentioned anti-CLEC12A nanobody or the above-mentioned antibody;
[0074] In an alternative embodiment, the immunoconjugate further comprises a therapeutic agent;
[0075] In an optional embodiment, the therapeutic agent includes at least one of an immune checkpoint-related agent, a toxin, a factor, a chemotherapeutic drug, a radionuclide, a kinase inhibitor, and a cytotoxic agent.
[0076] Immune checkpoint-related preparations include but are not limited to: antibodies to inhibitory second signal molecules, PD-L1 inhibitors, and PD-1 / PD-L1 monoclonal antibody drugs. The inhibitory second signal molecule can be PD-1; CTLA-4; PD-1 and CTLA-4.
[0077] Relevant biomarkers for immune checkpoint inhibitor treatment include PD-L1, MSI / bMSI, TMB / bTMB, TNB, EGFR mutation, ALK fusion, TP53 mutation, and KRAS mutation.
[0078] In an alternative embodiment, the pharmaceutical composition comprises at least one of a pharmaceutically acceptable excipient, a carrier and a diluent.
[0079] In a seventh aspect, the present invention further provides a chimeric antigen receptor, the antigen binding domain of which comprises the above-mentioned anti-CLEC12A nanobody or the above-mentioned antibody.
[0080] In an alternative embodiment, the chimeric antigen receptor further comprises a signal peptide, a hinge region, a transmembrane region and a signal transduction domain.
[0081] In an optional embodiment, the signal transduction domain is selected from at least one of CD3ζ, 4-1BB (CD137), CD27, CD30, CD40, CD54, CD83, PD-1, ICOS (CD278), lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, CD270, CD273, CD274, DAP10, CLEC12A3, CD134, CD150 and CD152;
[0082] In an alternative embodiment, the signal transduction domain includes CD3ζ and 4-1BB intracellular regions;
[0083] In an optional embodiment, the transmembrane region is one or more of a CD28 transmembrane domain, a CD8 transmembrane region, a CD134 transmembrane region, a CD137 transmembrane region, an ICOS transmembrane region, and a DAP10 transmembrane region;
[0084] In an optional embodiment, the hinge region is one or more of an IgG1 FC-CH2-CH3 hinge region, an IgG2 FC-CH2-CH3 hinge region, an IgG4 FC-CH2-CH3 hinge region, a CD28 hinge region, and a CD8α hinge region;
[0085] In an alternative embodiment, the signal peptide is a CD8α signal peptide, an IL-2 signal peptide or a GM-CSF signal peptide.
[0086] In an eighth aspect, the present invention further provides a CAR-T cell targeting CLEC12A, comprising the chimeric antigen receptor described above;
[0087] In an optional embodiment, the CAR-T cells are selected from at least one of allogeneic universal CAR-T cells (UCAR-T) and autologous CAR-T cells;
[0088] In an optional embodiment, the universal CAR-T cells are CAR-T cells in which the B2M and TRAC genes are knocked out.
[0089] In a ninth aspect, the present invention further provides an anti-CLEC12A nanobody, an antibody, a nucleic acid molecule or a recombinant vector containing a nucleic acid molecule, a host cell, a chimeric antigen receptor or a CAR-T cell for use in any of the following:
[0090] (1) Application in the preparation of products for the prevention or treatment of tumors;
[0091] (2) Preparation and testing of CLEC12A products;
[0092] (3) preparing combination therapeutic drugs;
[0093] (4) Inhibit the proliferation of tumor cells.
[0094] In application (1), in an optional embodiment, the product includes: at least one of an immune cell, a reagent, a kit, a drug, and a pharmaceutical composition;
[0095] In an optional embodiment, the product for treating tumors includes a drug that targets CLEC12A to treat or assist in treating tumors;
[0096] In an optional embodiment, the tumor is a primary tumor or a secondary tumor. The tumor includes at least one of acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome;
[0097] In application (2), the product is a reagent, a kit or a gene chip.
[0098] In actual use, those skilled in the art can select a suitable marker according to the detection conditions or actual needs. No matter which marker is used, it belongs to the protection scope of the present invention.
[0099] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0100] Example 1 Screening and preparation of anti-CLEC12A protein nanobodies
[0101] 1. Expression and purification of CLEC12A recombinant protein
[0102] The recombinant plasmid pVax-CLEC12A(ECD)-mFc containing the CLEC12A extracellular segment gene was transfected into HEK293T cells. After 5 days of expression, the culture supernatant was collected and purified by affinity chromatography using an NTA-Ni column to obtain a high-purity recombinant protein CLEC12A-mFc.
[0103] 2. Animal Immunization
[0104] The CLEC12A-mFc recombinant protein (1 mg) was mixed with an equal volume of aluminum adjuvant and then immunized subcutaneously in the neck and back of Bactrian camels for four consecutive times. Peripheral blood was collected on the 7th day after the impact immunization.
[0105] 3. Construction and panning of VHH phage antibody library
[0106] (1) Isolation of peripheral blood lymphocytes
[0107] Peripheral blood anticoagulated blood was collected aseptically from the jugular vein and diluted with an equal volume of RPMI-1640 medium. Peripheral blood lymphocytes were then separated using Ficoll-Paque Plus lymphocyte separation medium. The obtained lymphocytes could be directly used to extract total mRNA or frozen at -80°C for later use.
[0108] (2) VHH gene amplification
[0109] Total mRNA was extracted from lymphocytes and reverse transcribed to obtain cDNA. The VHH gene was amplified by nested PCR. The primers used in the first round of PCR were (CALL001; CALL002), and agarose gel electrophoresis was used to separate and recover a band of about 700 bp. The recovered 700 bp product was then used as a template for the second round of PCR amplification (VHH-FOR; VHH-REV), and agarose gel electrophoresis was used to separate and recover a band of 400 bp.
[0110] Table 1 Primer sequences required for VHH gene amplification
[0111]
[0112] (3) Construction of VHH phage display vector
[0113] The recovered 400 bp PCR product and phage display vector pMECS were double-digested with Pst I and Not I, and then ligated with T4 DNA ligase.
[0114] (4) Electroporation
[0115] The ligation product was electroporated into E. coli TG1 competent cells and spread on LB / Amp-Glu plates. After culturing at 37°C overnight, the bacterial lawn was collected and stored with glycerol to prepare the phage library.
[0116] (5) Phage library diversity and library capacity determination
[0117] The electroporation product was diluted 10-fold and then spread on LB / Amp-Glu plates. After culturing at 37°C for 12 h, the number of transformants was calculated, and the final library capacity was 5.68×10 9 of phage libraries.
[0118] (6) Screening of anti-CLEC12A protein specific nanobodies
[0119] First, the purified CLEC12A-His recombinant protein (2 μg / mL) was coated on a 96-well ELISA plate, and the plate was blocked with 3% skim milk powder at 37°C for 1 h the next day. 1×1010 Recombinant phage containing nanobodies were incubated at 37℃ for 1h and then washed 5 times with PBST. Phages bound to CLEC12A-His were eluted with 0.1M glycine (pH=1.5) and neutralized with 1M Tris-HCl (pH=8.0). The eluate was re-infected with host bacteria TG1 and expanded for 3 rounds of screening. 96 clones were randomly selected for expansion and monoclonal ELISA was used to identify nanobodies that can specifically bind to CLEC12A protein. The results showed that 83 of the 96 clones were positive clones (P / N>3.0, P represents the OD450 value of the CLEC12A well, and N represents the OD450 value of the control well); a total of 4 anti-CLEC12A specific nanobodies were obtained.
[0120] (7) Specificity analysis of anti-CLEC12A protein nanoantibodies
[0121] The recombinant supernatant of the four nanoantibodies screened in (6) was used as the primary antibody and incubated with CLEC12A recombinant protein and other irrelevant antigens (BCMA-mFc, CD123-mFc, CD22-His, Siglec6-His, CD47-mFc and B7H3-His), and detected using HRP anti-M13 antibody. The results are as follows: Figure 1 As shown, the 4 obtained nanobodies were able to bind to the CLEC12A protein and did not react with other unrelated antigens, indicating that the above nanobodies all had good specific binding activity.
[0122] Example 2 Preparation of anti-CLEC12A protein specific nanobody
[0123] The plasmid containing the nanobody gene in step (6) of Example 1 was used as a template to amplify the VHH gene and construct it into the eukaryotic expression vector pcDNA3.1-MCS-hFc by homologous recombination. After successful construction, it was transfected into HEK293T cells. After expression for 5 days, the supernatant was collected and purified by affinity chromatography using an NTA-Ni column to obtain a recombinant nanobody (such as Figure 2 The sequence of the nanobody is shown in Table 2 below.
[0124] Table 2 Amino acid composition of Nanobodies of the present invention
[0125]
[0126] Example 3 Anti-CLEC12A protein nanobody and antigen binding detection
[0127] The four specific nanobodies prepared in Example 2 and the anti-CLEC12A-scFv antibody (M26) (patent number CN113248621A) of Guangzhou Baiji Gene Technology Co., Ltd. were co-incubated with the CLEC12A recombinant protein (200 ng / well) coated in the ELISA plate as positive controls, and detected using HRP goat anti-human antibody. The results are as follows: Figure 3 As shown, the results show that the above-mentioned nanoantibodies have good binding activity with CLEC12A protein.
[0128] Example 4 Affinity detection of nanobody and CLEC12A protein
[0129] The recombinant nanobody and the positive control antibody (M26-scFv) were respectively tested for binding affinity with the antigen CLEC12A-His (Sino Biological, Cat: 11896-H07H) coated on the CM5 chip using the Biacore 8k instrument. The results are shown in Table 3. The affinity of the anti-CLL1 nanobody to the CLEC12A protein was 10 -10 M, significantly higher than the affinity of the positive antibody M26.
[0130] Table 3 Binding affinity and kinetic analysis of anti-CLEC12A nanobodies to CLEC12A protein
[0131] Antibody Binding rate ka (1 / M*s) Dissociation rate kd (1 / s) Affinity KD(M) 22 1.10E+06 8.73E-04 7.94E-10 26 3.32E+06 5.74E-04 1.73E-10 41 3.42E+06 2.29E-03 6.69E-10 43 1.11E+06 5.03E-04 4.54E-10 M26 6.71E+06 6.99E-02 1.04E-08
[0132] Example 5 Flow cytometry detection of the binding of recombinant nanobodies to AML cell lines
[0133] The recombinant nanobodies Nb22, Nb26, Nb41, Nb43 prepared in Example 2 and the positive control antibody M26-scFv (2.5 μg / mL) against CLL1 from Guangzhou Baiji were incubated with AML cell lines THP-1 and U937 at 37°C for 40 min, washed 3 times with PBS, and then incubated with APC@goat anti-human antibody. After washing 3 times with PBS, the cells were analyzed by flow cytometry. The results are as follows: Figure 4 As shown, the results showed that the recombinant nanoantibodies Nb22, Nb26, Nb41, Nb43 and the positive control antibody M26 had good reactivity with THP-1 and U937 cells.
[0134] Example 6 Preparation of universal CAR-T cells
[0135] CRISPR gene editing technology was used to knock out the TRAC and B2M genes in healthy donor T cells to obtain TRAC - / B2M -T cells; the CAR lentivirus containing the CLEC12A nanobody gene of the present invention is infected with the TRAC - / B2M - Universal CAR-T cells are prepared from T cells. The results of in vitro and in vivo killing experiments show that the CLEC12A-targeted allogeneic universal CAR-T cells prepared by the present invention have good anti-tumor activity. It can be used to treat CLEC12A-positive tumors, including at least one of acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome.
[0136] Specifically, UCAR-T cell preparation
[0137] (1) Knockout of B2M and TRAC genes
[0138] Peripheral blood of healthy donors was collected and lymphocytes were isolated. CD3 / CD28 magnetic beads were used to stimulate the proliferation of activated T cells to obtain high-purity T cells. Then, sgRNA targeting B2M and TRAC (Table 4) and Cas9 protein complex were electroporated into T cells. Flow cytometry results 72 hours after electroporation showed that the knockout efficiencies of B2M and TRAC genes were 36.70% and 42.29%, respectively (Figure 4). Figure 5 As shown), high-purity B2M- / TRAC-T cells were obtained by reverse purification using magnetic beads containing anti-β2m and HLA antibodies.
[0139] Table 4 sgRNA sequences for knocking out B2M and TRAC genes
[0140] sgRNA name Sequence number sgRNA sequence TRAC-sgRNA-1 SEQ ID No.25 ACAAAACTGTGCTAGACATG TRAC-sgRNA-2 SEQ ID No.26 CTTCAAGAGCAACAGTGCTG B2M-sgRNA-1 SEQ ID No.27 CGCGAGCACAGCTAAGGCCA B2M-sgRNA-2 SEQ ID No.28 ACTCACGCTGGATAGCCTCC
[0141] (2) Construction of CAR lentiviral vector
[0142] The anti-CLEC12A humanized nanobody plasmid of the present invention was used as a template to amplify the antibody gene targeting CLEC12A and cloned into the pSLCAR-BBz plasmid by homologous recombination to construct a second-generation CAR, which mainly comprises the following elements: CD8α signal peptide, antigen binding domain, CD8α hinge region, CD28 transmembrane domain, 4-1BB intracellular signal transduction domain and CD3ζ signal transduction domain ( Figure 6 ).
[0143] (3) Preparation of UCAR-T cells by lentiviral infection
[0144] The CAR lentiviral plasmid prepared in the present invention was co-transfected with the packaging plasmids psPAX2 and pMD2.G into HEK293T cells, and the cell supernatant was collected and concentrated by ultracentrifugation to obtain the CAR lentivirus, which was then infected with B2M- / TRAC-T cells to prepare UCAR-T cells. The positive rates of CAR in different UCART cells in the present invention are as follows: Figure 7 As shown, the expression efficiency of CAR in 22-UCART, 26-UCART, 41-UCART, 43-UCART, M26-UCART and 1-UCART cells were 84.08%, 79.99%, 84.67%, 79.77%, 74.49% and 74.50%, respectively, indicating that the UCAR-T cells were successfully prepared, among which 1-UCART was the control UCAR-T cell targeting PSMA prepared by the present invention, and the sequence of the nanoantibody against PSMA protein referred to patent CN202211408304.2.
[0145] In order to exclude the influence of UCART itself on the experimental results, this experiment set up UCART targeting the irrelevant target PSMA for illustration.
[0146] Example 7 In vitro anti-tumor experiment of CLEC12A-UCART cells
[0147] The anti-tumor effect of CLEC12A-UCART cells was detected by in vitro co-culture experiments; THP-1 and U937 cells (CLEC12A positive) purchased from ATCC were prepared into cell lines THP-1-luciferase and U937-luciferase that stably expressed luciferase, and co-cultured with UCAR-T cells at different effector-target ratios (4:1, 2:1, 1:1 and 1:2) for 24 hours, and then luciferin potassium salt was added to react in the dark for 5 minutes, and the fluorescence intensity was detected in an ELISA instrument and the killing efficiency was calculated. The results are as follows Figure 8 As shown, the killing activity of anti-CLEC12A allogeneic universal CAR-T cells 22-UCART, 26-UCART, 41-UCART and 43-UCART against THP-1 and U937 cells was superior to that of the positive M26-UCART cells in the prior art (P<0.05).
[0148] Example 8 In vivo detection of anti-tumor activity of universal CAR-T cells in AML mouse transplantation model
[0149] The cell lines THP-1-luciferase and U937-luciferase that stably expressed luciferase were cultured at 1×10 6The cells were inoculated into 6-8 week old NCG mice through the tail vein. After inoculation, the tumor growth was detected in the in vivo imaging instrument and the mice were randomly divided into 6 groups, 5 mice in each group. On the 15th day after inoculation of tumor cells, UCAR-T cells targeting CLEC12A and control UCAR-T cells (1-UCART) were inoculated through the tail vein, and the blank control group was inoculated with the same volume of PBS. The survival status of each mouse in the experimental group and the control group was observed and counted for 45 days. The survival curve of mice was drawn by Kaplan-Meier method and the differences in survival of mice in each group were statistically compared by log-rank (Mantel-Cox) test.
[0150] The results are as follows Fig. 9 As shown, the survival of the UCAR-T cell group targeting CLEC12A was significantly longer than that of the negative control group (1-UCART) and the blank control group (PBS) (P<0.0001), indicating that the UCAR-T cells targeting CLEC12A in the present invention effectively controlled the proliferation and growth of AML cells and significantly prolonged the survival of mice.
[0151] The above experimental results collectively illustrate that the present invention has screened out anti-CLEC12A nanoantibodies with high affinity, and prepared allogeneic universal CAR-T cells targeting CLEC12A based on the nanoantibodies, which have excellent tumor cell killing activity and can be used as a therapeutic drug for acute myeloid leukemia. The source is not limited and it can also be mass-produced, providing a new option for the development of acute myeloid leukemia drugs.
Claims
1. A nanobody against CLEC12A (C-type lectin domain family 12 member A), characterized in that: The heavy chain variable region of the nanobody comprises CDR1, CDR2 and CDR3, the amino acid sequence of CDR1 is shown in SEQ ID No.5, the amino acid sequence of CDR2 is shown in SEQ ID No.6, and the amino acid sequence of CDR3 is shown in SEQ ID No.
7.
2. The anti-CLEC12A Nanobody according to claim 1, characterized in that: Satisfy at least one of the following: The nanobody also includes a framework region, and the structure of its heavy chain variable region is: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4; Or the nanobody is at least one of a monovalent nanobody and a multivalent nanobody; Or when the antibody is a monovalent nanobody, the amino acid sequence of the heavy chain variable region of the nanobody is shown in SEQ ID No.
8.
3. A nucleic acid encoding the anti-CLEC12A Nanobody according to claim 1 or 2.
4. A heavy-loaded vector comprising the nucleic acid of claim 3.
5. The recombinant vector according to claim 4, characterized in that: The recombinant vector is a plasmid or a virus; the virus is an adenovirus, an adeno-associated virus, a retrovirus or an oncolytic virus.
6. A host cell comprising the nucleic acid of claim 3 or the recombinant vector of any one of claims 4 or 5.
7. A pharmaceutical composition comprising the anti-CLEC12A Nanobody according to claim 1 or 2; the pharmaceutical composition comprises at least one of a pharmaceutically acceptable excipient, carrier or diluent.
8. A chimeric antigen receptor, characterized in that: The chimeric antigen receptor comprises a CD8α signal peptide, an antigen binding domain, a CD8α hinge region, a CD28 transmembrane domain, a 4-1BB intracellular signal transduction domain and a CD3ζ signal transduction domain from the N-terminus to the C-terminus, and the antigen binding domain is the anti-CLEC12A nanobody according to claim 1 or 2.
9. A CLEC12A-targeting CAR-T cell comprising the chimeric antigen receptor of claim 8.
10. The CAR-T cell targeting CLEC12A according to claim 9, characterized in that: The CAR-T cells are selected from at least one of allogeneic universal CAR-T cells and autologous CAR-T cells.
11. The CAR-T cell targeting CLEC12A according to claim 10, characterized in that: The allogeneic universal CAR-T cells are CAR-T cells with B2M and TRAC genes knocked out.
12. Use of the anti-CLEC12A nanobody according to claim 1 or 2, the nucleic acid according to claim 3, the recombinant vector according to claim 4 or 5, the host cell according to claim 6, the pharmaceutical composition according to claim 7, the chimeric antigen receptor according to claim 8, or the CAR-T cell according to any one of claims 9 to 11 in any of the following; a. Preparing immune cells, drugs or pharmaceutical compositions for treating tumors; the tumor is acute myeloid leukemia; b. Prepare reagents, kits or gene chips for detecting CLEC12A.
